Who was studied, and how
One number in the abstract
Where each one falls
Where it lands on the map
people with dyslipidemia, in this paper
Already taking rosuvastatin, or nottheir own situation, not assigned
on rosuvastatin
placebo
Rosuvastatin went with higher VLDL1-ApoB catabolism48×
correlation, not a testthe abstract, start to end
… in the catabolism of VLDL1-ApoB (48%), VLDL2-ApoB (63%) and …
← favours treatmentfavours comparator →
could be chanceNo interval given · direction only, strength unknown
VLDL1-ApoB catabolismrosuvastatin vs placebo, in type 2 diabetic patients
RR 48
StatinsLipids
1 / 4